← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Oncoimmune, Ltd
Ann Arbor, MI
$1,560,336
Total funding
6
Grants
Funding mix
By agency
NIH$1,560,336 · 6
By mechanism
R44$865,476 · 1
R43$374,654 · 3
R41$320,206 · 2
Investigators at Oncoimmune, Ltd
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
CD24 as therapeutic target for multiple sclerosis-phase2$502,000
R44 · FY2004 · NS
CD24 as therapeutic target for multiple sclerosis-phase2$363,476
R44 · FY2005 · NS
Human gene knock-in mice and anti-cancer antibodies$164,643
R41 · FY2001 · CA
Wild type Ras as cancer therapeutic agent$155,563
R41 · FY2001 · CA
Endothelial Cells as Gene Vehicles for MS Therapy$145,246
R43 · FY2003 · NS
GDP-bound Ras mutant RasN17N69 as a therapeutic agent$116,416
R43 · FY2002 · CA
CD24 as a therapeutic target for Multiple Sclerosis$112,992
R43 · FY2001 · NS